HK1100260A1 - Binding peptidomimetics and uses of the same - Google Patents

Binding peptidomimetics and uses of the same

Info

Publication number
HK1100260A1
HK1100260A1 HK07104723.9A HK07104723A HK1100260A1 HK 1100260 A1 HK1100260 A1 HK 1100260A1 HK 07104723 A HK07104723 A HK 07104723A HK 1100260 A1 HK1100260 A1 HK 1100260A1
Authority
HK
Hong Kong
Prior art keywords
monomers
nucleic acid
disclosed
acid molecule
same
Prior art date
Application number
HK07104723.9A
Other languages
English (en)
Inventor
Mark I Greene
Ramachandran Murali
Hongtao Zhang
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of HK1100260A1 publication Critical patent/HK1100260A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/521Chemokines
    • C07K14/522Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0089Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK07104723.9A 2004-02-20 2007-05-03 Binding peptidomimetics and uses of the same HK1100260A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54622404P 2004-02-20 2004-02-20
PCT/US2005/005383 WO2005081898A2 (fr) 2004-02-20 2005-02-18 Peptidomimetiques de liaison et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
HK1100260A1 true HK1100260A1 (en) 2007-09-14

Family

ID=34910756

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07104723.9A HK1100260A1 (en) 2004-02-20 2007-05-03 Binding peptidomimetics and uses of the same

Country Status (8)

Country Link
US (1) US7906624B2 (fr)
EP (2) EP2392586A1 (fr)
JP (1) JP2007528725A (fr)
AT (1) ATE536367T1 (fr)
AU (1) AU2005216126B2 (fr)
CA (1) CA2556832A1 (fr)
HK (1) HK1100260A1 (fr)
WO (1) WO2005081898A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE483466T1 (de) 2002-05-23 2010-10-15 Univ Pennsylvania Fas peptid-mimetika und ihre verwendungszwecke
JP2010526091A (ja) * 2007-04-30 2010-07-29 インテザイン テクノロジーズ, インコーポレイテッド 癌の処置のための生物学的な標的基の改変
US20100226925A1 (en) * 2007-09-14 2010-09-09 Amgen Inc. Homogeneous Antibody Populations
SG186076A1 (en) 2010-05-28 2013-01-30 Univ Texas Oligo-benzamide compounds and their use
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US8835493B2 (en) 2011-11-23 2014-09-16 Board Of Regents, The University Of Texas System Oligo-benzamide compounds for use in treating cancers
WO2013078277A1 (fr) 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Composés d'oligo-benzamides et leur utilisation dans le traitement de cancers
AU2015231001A1 (en) 2014-03-21 2016-09-29 Abbvie Inc. Anti-EGFR antibodies and antibody drug conjugates
WO2017015064A1 (fr) * 2015-07-20 2017-01-26 The Board Of Trustees Of The Leland Stanford Junior University Phénotypage de détection et quantification de cellules à l'aide d'un réactif de liaison multimère
BR112018075649A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
JP6751165B2 (ja) 2016-06-08 2020-09-02 アッヴィ・インコーポレイテッド 抗b7−h3抗体及び抗体薬物コンジュゲート
CA3027044A1 (fr) 2016-06-08 2017-12-14 Abbvie Inc. Anticorps anti-b7-h3 et conjugues anticorps-medicaments
BR112018075630A2 (pt) 2016-06-08 2019-03-19 Abbvie Inc. anticorpos anti-cd98 e conjugados de fármaco de anticorpo
EP3612567B1 (fr) 2017-04-19 2024-09-11 Bluefin Biomedicine, Inc. Anticorps anti-vtcn1 et conjugués anticorps-médicament
CN107236046B (zh) * 2017-05-15 2021-05-07 江苏吴中医药集团有限公司苏州中凯生物制药厂 一种重组人内皮抑素融合蛋白及其制备方法和应用
CN111278847B (zh) 2017-07-10 2024-04-19 斯坦福国际研究院 分子导向系统肽及其用途
WO2019014199A1 (fr) * 2017-07-10 2019-01-17 Sri International Conjugué de saporine peptidique pour le traitement du cancer
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334702A (en) 1991-03-25 1994-08-02 University Of Illinois Compositions which are immunologically crossreactive with antibodies and preparative methods therefor
US5665539A (en) * 1991-07-12 1997-09-09 The Regents Of The University Of California Immuno-polymerase chain reaction system for antigen detection
US5328985A (en) * 1991-07-12 1994-07-12 The Regents Of The University Of California Recombinant streptavidin-protein chimeras useful for conjugation of molecules in the immune system
US6391590B1 (en) * 1991-10-21 2002-05-21 The Regents Of The University Of California Recombinant streptavidin-metallothionein chimeric protein having biological recognition specificity
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
US6100377A (en) 1994-06-10 2000-08-08 The Trustees Of The University Of Pennsylvania Constrained peptides
US5663144A (en) 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
US6497881B1 (en) * 1995-11-30 2002-12-24 New York University High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
WO1997034634A1 (fr) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Produits de recombinaison d'anticorps diriges contre le gd2, constitues d'un fragment variable (fv) a chaine simple
US5922553A (en) * 1996-11-21 1999-07-13 Trustees Of The University Of Pennsylvania Method of detecting protein by immuno RNA
CA2315944A1 (fr) * 1997-12-24 1999-07-08 Diatech Pty. Ltd. Molecules bifonctionnelles
CA2340595A1 (fr) * 1998-08-25 2000-03-02 University Of Washington Mutants de streptavidine comportant des domaines fonctionnels secondaires
US7144991B2 (en) * 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US6743592B1 (en) * 2000-07-25 2004-06-01 The Trustees Of The University Of Pennsylvania Methods, systems and kits for immuno-detection of epitopes expressed on molecules
US7524628B2 (en) * 2000-07-25 2009-04-28 The Trustees Of The University Of Pennsylvania Method for detecting molecules expressing a selected epitope via fluorescent dyes
US7045286B2 (en) * 2000-07-25 2006-05-16 The Trustees Of The University Of Pennsylvania Methods of detecting molecules expressing selected epitopes via fluorescent dyes
US6998234B2 (en) 2000-11-03 2006-02-14 Oncotech, Inc. Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells
US7179785B2 (en) * 2001-11-21 2007-02-20 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same

Also Published As

Publication number Publication date
WO2005081898A2 (fr) 2005-09-09
JP2007528725A (ja) 2007-10-18
EP1718323A2 (fr) 2006-11-08
EP1718323B1 (fr) 2011-12-07
AU2005216126A1 (en) 2005-09-09
EP1718323A4 (fr) 2008-12-31
CA2556832A1 (fr) 2005-09-09
EP2392586A1 (fr) 2011-12-07
WO2005081898A3 (fr) 2006-02-02
ATE536367T1 (de) 2011-12-15
US7906624B2 (en) 2011-03-15
AU2005216126B2 (en) 2011-04-07
US20080206136A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
HK1100260A1 (en) Binding peptidomimetics and uses of the same
Wenzel et al. Conformational constraints in protein degradation by the 20S proteasome
NZ580378A (en) Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
HK1092481A1 (en) Polypeptides having binding affinity for her2
MX357562B (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas vip3a de bacillus thuringiensis y metodos para su uso.
PH12013502425A1 (en) Smoothened polypeptides and methods of use
FI3778885T3 (fi) Muokattujen ihmisen arginaasien koostumuksia ja menetelmiä syövän hoitamiseksi
ATE550041T1 (de) Transglutaminase-vermittelte konjugation von peptiden
HK1091217A1 (en) Tuberculosis vaccine with improved efficacy
WO2007018619A3 (fr) Agents therapeutiques chimeriques
AR059300A1 (es) Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
DE602005025141D1 (de) In Zellen eindringende Peptide als Träger für Moleküle
NZ334839A (en) Polynucleotide molecules encoding neospora proteins and uses thereof
EP1842911A4 (fr) Peptides se liant au hla, fragments d'adn codant pour lesdits peptides et vecteurs recombinants
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
IL174645A0 (en) MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
TW200604207A (en) A superantigen fusion protein and the use thereof
WO2010117997A3 (fr) Ciblage peptidique des cellules de l'oreille interne
WO2005058944A3 (fr) Peptides immunogenes de xage-1
DE10394174D2 (de) Peptide mit hohem Cysteingehalt
EP1221485A3 (fr) Acides nucléiques codant pour des protéines de Neospora
GB0520568D0 (en) Receptor
TH85387B (th) อินเทอร์เฟอรอน-อัลฟา โพลีเทปไทด์ และคอนจูเกต
CO5400145A1 (es) Proteina asociada con enfermedad
MY134618A (en) Filarial parasite polypeptides and sequences, gene sequences and uses thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190221